<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586963</url>
  </required_header>
  <id_info>
    <org_study_id>07-006142</org_study_id>
    <secondary_id>IRUSESOM0488</secondary_id>
    <nct_id>NCT00586963</nct_id>
  </id_info>
  <brief_title>Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis</brief_title>
  <acronym>EE</acronym>
  <official_title>How Does Proton Pump Inhibitor Therapy Impact Quality of Life in Patients Newly Diagnosed With Erosive Reflux Esophagitis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to for two reasons:&#xD;
&#xD;
        -  To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux&#xD;
           esophagitis) has on your esophagus when taken correctly.&#xD;
&#xD;
        -  To learn about the quality of life changes (good and bad) you may experience with this&#xD;
           medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The plan is to have 50 people take part in this study at Mayo Clinic Rochester. This research&#xD;
      study is looking at people who have a new condition called erosive reflux esophagitis.&#xD;
      Esophagitis is defined as mucosal damage produced by the abnormal reflux of gastric contents&#xD;
      into the esophagus. Acid reflux, over time, can wear away or erode the lining of your&#xD;
      esophagus. This condition is called erosive esophagitis. The treating physician may start you&#xD;
      on prescription strength acid reducing group of medications called Proton Pump Inhibitors&#xD;
      (PPI). PPI medications can provide 24-hour relief from your painful heartburn symptoms and it&#xD;
      can help you heal the erosions in the esophagus that acid reflux may cause.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">65</enrollment>
  <condition>Erosive Esophagitis</condition>
  <condition>Reflux Esophagitis</condition>
  <condition>GERD</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients age 18 and older, diagnosed with reflux esophagitis, being seen at Mayo Clinic&#xD;
        Rocheser.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Have either mild-to-moderate erosive reflux esophagitis&#xD;
&#xD;
          -  Meet criteria for GERD symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients already on esomeprazole therapy, have previously failed to respond to&#xD;
             esomeprazole, or are intolerant to PPI therapy.&#xD;
&#xD;
          -  Patients expected to travel outside of the United States during the initial 8 weeks of&#xD;
             PPI therapy.&#xD;
&#xD;
          -  Pregnant women will be excluded as PPI's are not thought safe for the fetus (Pregnancy&#xD;
             Category C). - Children younger than 18 years of age will be excluded.&#xD;
&#xD;
          -  Other vulnerable populations, such as those with diminished mental acuity, will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Romero, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55955</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>August 20, 2010</last_update_submitted>
  <last_update_submitted_qc>August 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yvonne Romero</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Erosive Esophagitis</keyword>
  <keyword>Reflux Esophagitis</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

